Literature DB >> 833581

Serum dopamine-beta-hydroxylase in parkinsonism.

E S Markianos, E Rüther.   

Abstract

Serum dopamine-beta-hydroxylase activities of a group of 16 parkinsonian patients under L-Dopa plus decarboxylase inhibitor showed a distribution with a drift towards higher activities compared to a group of normals of the same age range. Acute doses of L-Dopa failed to cause any change in the serum enzyme activities as well as in the serum concentration of 3-methoxy-4-hydroxyphenylethylene glycol, in parkinsonian patients and in normals. The data support the idea of a limited influence of L-Dopa on the noradrenaline synthesis and release in parkinsonism.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 833581     DOI： 10.1007/BF01250277

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  8 in total

1.  Serum dopamine beta-hydroxylase: assay and enzyme properties.

Authors:  E S Markianos; I E Nyström
Journal:  Z Klin Chem Klin Biochem       Date:  1975-07

2.  Serum dopamine-beta-hydroxylase activity in patients with Huntington's chorea and Parkinson's disease.

Authors:  A N Lieberman; L S Freedman; M Goldstein
Journal:  Lancet       Date:  1972-01-15       Impact factor: 79.321

3.  Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.

Authors:  T N Chase; E K Gordon; L K Ng
Journal:  J Neurochem       Date:  1973-09       Impact factor: 5.372

4.  Fusaric acid in Parkinson's disease.

Authors:  T N Chase
Journal:  Neurology       Date:  1974-07       Impact factor: 9.910

5.  Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen
Journal:  Arch Neurol       Date:  1973-02

6.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

7.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15

8.  A new dopamine- -hydroxylase inhibitor: effects on the noradrenaline concentration and on the action of L-DOPA in the spinal cord.

Authors:  N E Andén; K Fuxe
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739
  8 in total
  3 in total

1.  Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.

Authors:  P Riederer; W Birkmayer; D Seemann; S Wuketich
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

2.  Plasma dopamine-beta-hydroxylase and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease.

Authors:  H Coelho; M Azevedo; C Proença; J M e Silva; C Manso
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

3.  Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading.

Authors:  J Vardi; S Flechter; Z Oberman; M Allelov; J M Rabey; M Hertzberg; M Streifler
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.